Availability and eligibility require provider evaluation
Side-by-Side: DAC vs No-DAC | Side Effect | DAC | No-DAC | |---|---|---| | Flushing | Moderate | Mild | | Headache | Mild | Mild | | Water retention | Mild to moderate | Minimal | | Tingling | Reported more | Reported less | | Vivid dreams | Reported less | Reported more | | Insulin sensitivity over time | Higher theoretical concern | Lower | And for the record, here's what CJC-1295 does not typically cause at compounded doses: significant cortisol elevation, significant prolactin elevation, severe hunger spikes (that's GHRP-6's territory), mood changes, acute hypoglycemia, or acromegalic changes
Harris, T
Due to an inability of performing NMR-imaging on the required patients needed to adhere to the initial power calculation of the primary endpoint, liver fat, an amendment was added to the protocol allowing the inclusion of an additional 10 patients
[DOI] [PMC free article] [PubMed] [Google Scholar] 83.Adema AY, de Roij van Zuijdewijn CLM, Hoenderop JG, de Borst MH, Ter Wee PM, Heijboer AC, Vervloet MG, NIGRAM consortium Influence of exogenous growth hormone administration on circulating concentrations of -klotho in healthy and chronic kidney disease subjects: a prospective, single-center open case-control pilot study